Skip to content

Marc Beer, CEO Of Aegerion Pharmaceuticals, Discusses Orphan Drug Lomitapide: Bloomberg TV

December 24, 2012

The Orphan Druganaut Blog has followed since the October 2012 FDA Advisory Committee meetings, the parallel step-by-step approval process of 2 orphan drugs, Aegerion Pharmaceuticals’ Lomitapide and Genzyme and Isis Pharmaceuticals’ Kynamro (Mipomersen).  Both drugs are in a battle for the same indication in the US – Homozygous Familial Hypercholesterolemia (HoFH).

Lomitapide is facing a FDA PDUFA date on or before December 28, 2012. In light of the upcoming catalyst, it is interesting to view the video of Aegerion Pharmaceuticals’ CEO. Marc Beer, CEO and Director at Aegerion Pharmaceuticals, discusses on Bloomberg TV, the October 2012 FDA Advisory Committee’s positive recommendation of Lomitapide for HoFH. Mr. Beer has been CEO of Aegerion Pharmaceuticals since August 2010.

In November 2012, Aegerion Pharmaceuticals publishes in the Lancet, data from its 78-week pivotal Phase III study of Lomitapide in adult patients with HoFH. Mr. Beer said, “We are pleased that the Lancet recognizes the importance of this research and the relevance of the findings in this rare disease with significant medical needs”. Here is the PubMed citation :

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Cuchel M, Meagher EA, et al. Lancet. 2012 Nov 1; pii: S0140-6736(12)61731-0. doi: 10.1016/S0140-6736(12)61731-0. [Epub ahead of print]. PMID: 23122768 [PubMed – as supplied by publisher].

Per a December 21, 2012 Motley Fool article titled, “3 Humongous Health-Care Stocks This Week”, Aegerion Pharmaceuticals’ stock :

  1. On December 14, 2012, hit a 52-week high after the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) gives a negative recommendation to Isis Pharmaceuticals’ Mipomersen for its Marketing Authorization for HoFH
  2. Continues to rise 17% for the week ending December 21, 2012
  3. Is up 33% since the FDA Advisory Committee’s recommendation for approval in October 2012.

References

***  Orphan Druganaut Blog Post titled, “Aegerion Pharmaceuticals’ Lomitapide Verses Genzyme’s Mipomersen: Battle of 2 Orphan Drugs”

Copyright © 2012-2013, Orphan Druganaut Blog. All rights reserved.

Advertisements
Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: